Brämswig Kira H, Knittelfelder Regina, Gruber Silke, Untersmayr Eva, Riemer Angelika B, Szalai Krisztina, Horvat Reinhard, Kammerer Robert, Zimmermann Wolfgang, Zielinski Christoph C, Scheiner Otto, Jensen-Jarolim Erika
Department of Pathophysiology, Medical University Vienna, Vienna, Austria.
Clin Cancer Res. 2007 Nov 1;13(21):6501-8. doi: 10.1158/1078-0432.CCR-07-0692.
The carcinoembryonic antigen (CEA) is a glycoprotein that is overexpressed in nearly 50% of all human and veterinarian tumors. At present, anti-CEA antibodies are being tested in clinical studies as passive immunotherapeutics. This study aims to establish an active immunotherapy for the poorly immunogenic CEA glycoprotein by generating antigen surrogates.
We used the monoclonal anti-CEA antibody Col-1 and the biopanning method to generate peptide mimics (mimotopes) of the Col-1 epitope. The peptide showing the highest specificity and mimicry was synthesized as an octameric multiple antigenic mimotope (MAM). Subsequently, immunogenicity of the selected mimotope was examined in BALB/c mice. We assessed antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity mediated by the induced antibodies on CEA-expressing HT29 tumor cells. Furthermore, after immunization, the BALB/c mice were transplanted s.c. with Meth-A/CEA tumor cells.
When BALB/c mice were immunized with this MAM, they generated a specific humoral immune response against CEA. The mimotope-induced polyclonal and poly-isotypic antibodies induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Furthermore, when MAM-immunized mice were transplanted s.c. with Meth-A/CEA cells expressing human CEA, a suppressed tumor growth was observed.
From our results, we can conclude that the Col-1 epitope of the glycoprotein CEA can be translated into an immunogenic peptide mimic. The mimotope-induced antibodies recognize CEA and do effectively inhibit growth of CEA-positive tumors. Based on these finding, we suggest that the generated mimotopes are candidates for active immunotherapy of CEA-expressing tumors.
癌胚抗原(CEA)是一种糖蛋白,在近50%的人类和兽医肿瘤中过度表达。目前,抗CEA抗体正在临床研究中作为被动免疫疗法进行测试。本研究旨在通过生成抗原替代物,为免疫原性较差的CEA糖蛋白建立一种主动免疫疗法。
我们使用单克隆抗CEA抗体Col-1和生物淘选方法来生成Col-1表位的肽模拟物(模拟表位)。将显示出最高特异性和模拟性的肽合成为八聚体多抗原模拟物(MAM)。随后,在BALB/c小鼠中检测所选模拟表位的免疫原性。我们评估了诱导抗体介导的对表达CEA的HT29肿瘤细胞的抗体依赖性细胞毒性和补体依赖性细胞毒性。此外,免疫后,将Meth-A/CEA肿瘤细胞皮下移植到BALB/c小鼠体内。
当用这种MAM免疫BALB/c小鼠时,它们产生了针对CEA的特异性体液免疫反应。模拟表位诱导的多克隆和多同种型抗体在体外诱导了抗体依赖性细胞毒性和补体依赖性细胞毒性。此外,当用表达人CEA的Meth-A/CEA细胞皮下移植MAM免疫的小鼠时,观察到肿瘤生长受到抑制。
从我们的结果可以得出结论,糖蛋白CEA的Col-1表位可以转化为具有免疫原性的肽模拟物。模拟表位诱导的抗体识别CEA并有效抑制CEA阳性肿瘤的生长。基于这些发现,我们建议所生成的模拟表位是表达CEA肿瘤主动免疫疗法的候选物。